Abstract:Alzheimer's disease (AD) is a neurodegenerative disorder with devastating symptoms, including memory impairments and cognitive deficits. Hallmarks of AD pathology are amyloid-beta (Aβ) deposition forming neuritic plaques and neurofibrillary tangles (NFTs). For many years, AD drug development has mainly focused on directly targeting the Aβ aggregation or the formation of tau tangles, but this disease has no cure so far. Other common characteristics of AD are synaptic abnormalities and dysfunctions such as synaptic damage, synaptic loss, and structural changes in the synapse. Those anomalies happen in the early stages of the disease before behavioural symptoms have occurred. Therefore, better understanding the mechanisms underlying the synaptic dysfunction found in AD and targeting the synapse, especially using early treatment windows, can lead to finding novel and more effective treatments that could improve the lives of AD patients. Researchers have recently started developing different disease-modifying treatments targeting the synapse to rescue and prevent synaptic dysfunction in AD. The main objectives of these new strategies are to halt synaptic loss, strengthen synaptic connections, and improve synaptic density, potentially leading to the rescue or prevention of cognitive impairments. This article aims to address the mechanisms of synaptic degeneration in AD and discuss current strategies that focus on the synapse for AD therapy. Alzheimer's disease (AD) is a neurodegenerative disorder that significantly impairs memory and causes cognitive and behavioural deficits. Scientists worldwide have tried to find a treatment that can reverse or rescue AD symptoms, but there is no cure so far. One prominent characteristic of AD is the brain atrophy caused by significant synaptic loss and overall neuronal damage, which starts at the early stages of the disease before other AD hallmarks such as neuritic plaques and NFTs. The present review addresses the underlying mechanisms behind synaptic loss and dysfunction in AD and discusses potential strategies that target the synapse.

Insights to develop tau‐directed therapeutics to protect the synaptic integrity for tauopathies

Potent of strategic approaches for tauopathies ranging from single-cell transcriptome to microbiome

Recent developments with tau-based drug discovery

Dynamic behaviors of α-synuclein and tau in the cellular context: New mechanistic insights and therapeutic opportunities in neurodegeneration

Tau: Enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies

Targeting synapse function and loss for treatment of neurodegenerative diseases

Targeting the Synapse in Alzheimer’s Disease

The synapse as a treatment avenue for Alzheimer’s Disease

Tau Acts in Concert With Kinase/Phosphatase Underlying Synaptic Dysfunction

Role of Tau Protein in Neurodegenerative Diseases and Development of Its Targeted Drugs: A Literature Review

Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer's Disease

The role of pathological tau in synaptic dysfunction in Alzheimer’s diseases

Etiological Insights and Degradation Strategies

Tau Protein and Tauopathies: Exploring Tau Protein‐Protein and Microtubule Interactions, Cross‐Interactions and Therapeutic Strategies.

Tauopathies: Mechanisms and Therapeutic Strategies

Degradation and Transmission of Tau by Autophagic-Endolysosomal Networks and Potential Therapeutic Targets for Tauopathy

Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration

Targeting Abnormal Tau Phosphorylation for Alzheimer's Therapeutics

Emerging Diagnostic and Therapeutic Strategies for Tauopathies

Disentangling tau: One protein, many therapeutic approaches

Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease